跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PMS-DEFERASIROX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PMS-DEFERASIROX
Authorized
STANDARD
PMS-DEFERASIROX
Pharmascience Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
139deb500b68d06e
Company
Pharmascience Inc
Type
Standard
Approval Details
Approval Id
139deb500b68d06e
Drug Approval Canada Name
PMS-DEFERASIROX
Product Name
PMS-DEFERASIROX
Status
Marketed
Status Date
2018-04-25
Original Market Date
2018-04-25
Din
02474328
Drug Class
Human
Dosage Form
Tablet For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
64:00.00
Atc Original
V03AC03 DEFERASIROX
Atc Name
v 03 ac 03
Aig Number
0151733001
Company Name
Pharmascience Inc
Company Address
100, 6111 Royalmount Ave, Montreal, Quebec, Canada, H4P 2T4
Company Detail Path
/organization/pharmascience-inc
Company Information
Pharmaceutical Company Name
Pharmascience Inc
Country Name
Canada
Province Name
Quebec
City Name
montréal,quebec,country_ca
Address
6111 av Royalmount bureau 100
Active Ingredients
DEFERASIROX
125 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
139deb500b68d06e
Type
Standard
Back to Health Canada Approvals